GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis
USA - NYSE:DNA - US37611X2099 - Common Stock
11.59 USD
-1.2 (-9.38%)
11.4 USD
-0.19 (-1.64%)
Overall DNA gets a fundamental rating of 4 out of 10. We evaluated DNA against 58 industry peers in the Life Sciences Tools & Services industry. While DNA has a great health rating, there are worries on its profitability. DNA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year DNA has reported negative net income.
In the past year DNA has reported a negative cash flow from operations.
In the past 5 years DNA always reported negative net income.
In the past 5 years DNA always reported negative operating cash flow.
1.2 Ratios
DNA's Return On Assets of -25.60% is on the low side compared to the rest of the industry. DNA is outperformed by 74.14% of its industry peers.
DNA's Return On Equity of -51.42% is on the low side compared to the rest of the industry. DNA is outperformed by 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.6% | ||
| ROE | -51.42% | ||
| ROIC | N/A |
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 78.99%, DNA belongs to the best of the industry, outperforming 98.28% of the companies in the same industry.
In the last couple of years the Gross Margin of DNA has declined.
The Profit Margin and Operating Margin are not available for DNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
2. Health
2.1 Basic Checks
DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DNA has been reduced compared to 5 years ago.
The debt/assets ratio for DNA has been reduced compared to a year ago.
2.2 Solvency
DNA has an Altman-Z score of -6.33. This is a bad value and indicates that DNA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.33, DNA is doing worse than 86.21% of the companies in the same industry.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.33 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
A Current Ratio of 5.41 indicates that DNA has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.41, DNA is doing good in the industry, outperforming 74.14% of the companies in the same industry.
DNA has a Quick Ratio of 5.41. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.41, DNA belongs to the best of the industry, outperforming 81.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.41 |
3. Growth
3.1 Past
DNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.95%, which is quite impressive.
Looking at the last year, DNA shows a very strong growth in Revenue. The Revenue has grown by 25.24%.
Measured over the past years, DNA shows a very strong growth in Revenue. The Revenue has been growing by 33.17% on average per year.
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%
3.2 Future
The Earnings Per Share is expected to grow by 14.86% on average over the next years. This is quite good.
DNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.59% yearly.
EPS Next Y40.65%
EPS Next 2Y22.84%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue Next Year-22.25%
Revenue Next 2Y-5.68%
Revenue Next 3Y2%
Revenue Next 5Y46.59%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DNA's earnings are expected to grow with 15.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.84%
EPS Next 3Y15.82%
5. Dividend
5.1 Amount
No dividends for DNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.59
-1.2 (-9.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners69.79%
Inst Owner Change0.19%
Ins Owners6.68%
Ins Owner Change0.03%
Market Cap651.36M
Revenue(TTM)230.81M
Net Income(TTM)-315194000
Analysts41.82
Price Target12.24 (5.61%)
Short Float %14.85%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.25%
Min EPS beat(2)6.02%
Max EPS beat(2)30.48%
EPS beat(4)3
Avg EPS beat(4)22.63%
Min EPS beat(4)-11.88%
Max EPS beat(4)65.88%
EPS beat(8)5
Avg EPS beat(8)1.14%
EPS beat(12)6
Avg EPS beat(12)0.21%
EPS beat(16)6
Avg EPS beat(16)-243.94%
Revenue beat(2)2
Avg Revenue beat(2)20.83%
Min Revenue beat(2)18.03%
Max Revenue beat(2)23.63%
Revenue beat(4)3
Avg Revenue beat(4)33.8%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)95.92%
Revenue beat(8)5
Avg Revenue beat(8)17.62%
Revenue beat(12)9
Avg Revenue beat(12)15.21%
Revenue beat(16)13
Avg Revenue beat(16)27.99%
PT rev (1m)5.88%
PT rev (3m)38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.69%
EPS NY rev (1m)0%
EPS NY rev (3m)14.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.06 | ||
| P/tB | 1.19 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.72
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-4.88
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS4.11
BVpS10.91
TBVpS9.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.6% | ||
| ROE | -51.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.99% | ||
| FCFM | N/A |
ROA(3y)-58.74%
ROA(5y)-56.67%
ROE(3y)-93%
ROE(5y)-85.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.07%
GM growth 5Y-4.27%
F-Score5
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 56.99% | ||
| Cap/Sales | 15.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.41 | ||
| Altman-Z | -6.33 |
F-Score5
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)93.32%
Cap/Depr(5y)178.3%
Cap/Sales(3y)18.24%
Cap/Sales(5y)29.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
EPS Next Y40.65%
EPS Next 2Y22.84%
EPS Next 3Y15.82%
EPS Next 5Y14.86%
Revenue 1Y (TTM)25.24%
Revenue growth 3Y-10.23%
Revenue growth 5Y33.17%
Sales Q2Q%-11.75%
Revenue Next Year-22.25%
Revenue Next 2Y-5.68%
Revenue Next 3Y2%
Revenue Next 5Y46.59%
EBIT growth 1Y42.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.89%
EBIT Next 3Y19.17%
EBIT Next 5Y41.47%
FCF growth 1Y25.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.97%
OCF growth 3YN/A
OCF growth 5YN/A
GINKGO BIOWORKS HOLDINGS INC / DNA FAQ
What is the ChartMill fundamental rating of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to DNA.
What is the valuation status of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
ChartMill assigns a valuation rating of 0 / 10 to GINKGO BIOWORKS HOLDINGS INC (DNA). This can be considered as Overvalued.
How profitable is GINKGO BIOWORKS HOLDINGS INC (DNA) stock?
GINKGO BIOWORKS HOLDINGS INC (DNA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for GINKGO BIOWORKS HOLDINGS INC?
The Earnings per Share (EPS) of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to grow by 40.65% in the next year.